Her2 Positive breast cancer has the following distinctive characteristics:
High risk of relapse transfer: Her2 positive breast cancer is easily re-emergible and transmissible, with a high degree of virulence. HER2 is an amplified gene, and positive represents an increase in the risk of a negative preset. For example, sher2 positive breast cancer patients are more likely to relapse and transfer, with a higher degree of malignity than Luminal-type breast cancer, and a lower rate of prognosis.
Unique clinical manifestations: Her2 positive breast cancer patients have typical symptoms, including the absence of smooth, unclear limits, and can also be seen in breast-leaving fluids, while breast tumours and tumours to the nipples can lead to emits and asymmetric changes in both sides of the nipples. There are also atypical manifestations, including the swelling of lymph knots in the armpit. The detection of antigens for cancer on tumours has increased significantly.
Poor pregnosis indicator: Breast cancer HeR2 is an important indicator of diagnosis, diagnosis and treatment. Her2 positive is a negative pre-post-indicator suggesting that tumours are prone to relapse. HeR2 positive breast cancer, with clinical characteristics and biological behaviour, and treatment patterns, is also very different from other types of breast cancer, when it is expressed that the breast cancer is extremely resistant to growth, invasion and extinction and that it is poorly prepared.
Relation to other indicators: Immunization indicators for breast cancer include ER, PR, Her2 and Ki67, Her2 is a human skin growth factor receptor, a trans-film cheese amino acid anesthesia receptor, which plays an important role in promoting cell division, transfer, breeding and fragmentation, and is a very important post-chanceal cancer prognosis factor. Her2 positives represent poor patient prognosis, while also increasing the risk of lymphorate transfer, Her2 positive breast cancers are more invasive and disease prognosis is poor. If all three of the above indicators are negative, they are called triple-negative breast cancer, which is relatively poor.
II. Main treatment methods
(i) Surgery Breastpaste: For patients with smaller tumours and HeR2 positives, the combination of breastpaste can have a therapeutic effect similar to that of breast hysterectomy. Breast cancer milk is relatively effective, and a full assessment of the patient ‘ s condition is made prior to the breast milk operation, which, if there is a history of treatment, a multi-clinic stove or a previous procedure, does not make it possible to opt for breast milk. Breast-painting can retain breasts, the procedure is less traumatic and quick to recover and has less impact on normal life later in life, but after the operation, the patient is treated in combination with other treatment to reduce the risk of relapse. We have an overall breast cancer breastfeeding rate of less than 20 per cent and, despite the enormous physical and psychological trauma caused to women, mammography remains the preferred treatment for most breast cancer patients. The expert calls for breast cancer to benefit from survival and quality of life, and for more patients to be able to return to their families and society in a more satisfactory manner through standardized treatment and long-term good management. Breast hysterectomy: Breast hysterectomy may be required if the tumour is large or if there is a transfer of lymph nodes in the armpit.
chemotherapy is one of the most important means of comprehensive breast cancer treatment, which can kill cancer cells throughout the body and prevent relapse and diversion. Commonly used chemotherapy drugs include vixasol, Dossitas, cyclophosphorous amide, etc.
(iii) Releases can partially irradiate the tumor, kill residual cancer cells and reduce the risk of relapse and diversion. The therapeutic function is to kill cancer cells, but it can also cause damage to normal cells and damage to patient tissues, resulting in signs of reduced immunity, vomiting, anaemia, reduction of white cells, bone marrow inhibition and lung fibrosis. Patients are advised to strengthen selenium supplementation during treatment.
(iv) Target treatment
1. Her2 Positive breast cancer patients can be treated with target-oriented drugs, such as tutos monotony, Pattos monotony, etc. These drugs can be specific to HeR2 positive cells and inhibit tumor growth. Breast cancer Her2 positive target drug, most of which is anti-torture, others are anti-torture, Lapatini, Nairatini, Cordini, etc. The curtoric monovalent resistance is a recombinant, DNA-derived, single-sourced IgG1 antibody, which selectively acts on the outside of the HeR-2 cell, inhibits the activation of the HeR-2 receptor, accelerates the internalization, degradation of the HeR-2 protein receptor, and enhances cytological attacks and oncology target cells by cytologically dependent on cell-mediated cytotoxic effects.
2. For the HeR2 gene overexpression of small breast cancers, a single anti-target treatment for tutoballs prepared by GMO technology can be selected, which can significantly reduce the post-operative recurrence rate and increase the prognosis. For persons with transgenic breast cancer, HER2 genetic overexpression, a single anti-target treatment for tratocols prepared by GMO technology is available, which can significantly reduce post-operative relapse rates and increase the prognosis.
(v) Endocrine treatment. Endocrine treatment applies to hormonal receptor-positive breast cancer and slows the growth of tumours by inhibiting estrogen generation or effects. The most common endocrinological treatments include his mosaics, carcasses, etc. Endocrine treatment is one of the comprehensive treatments for breast cancer, which applies to hormonal receptor-positive and Her2 positive breast cancer patients. hormonal receptor-positive breast cancer patients are treated mainly with detoxin antigen delivery, and most commonly with mosaics, Toremifen, etc. For post-menopausal breast cancer patients, aromatic enzyme inhibitors can also be selected for treatment, and clinically commonly used drugs include curvatures, anacondas, etc. Targeting treatment can also be provided to post-polythetic hormonal positive breast cancer patients, as prescribed by the medical authorities, with the use of viol, Pato Jole, etc. In the molecular stratification of breast cancer, breast cancer of luminal A, breast cancer of luminal B and hormonal positive breast cancer of Her-2 positive breast cancer are suitable for endocrine treatment. Hormonal receptors are described here as estrogen receptors (ERs) and pregnant ketone receptors (PRs). For both receptors, whether positive or negative, the results of the tissue pathology of breast cancer are reported in detail. As long as one of the two receptors is positive, it is suitable for endocrine treatment.
Principles for developing treatment programmes
Programmes to treat Sher2-positive breast cancer need to be designed with a combination of multiple factors. First, the appropriate treatment should be chosen on the basis of the patient ‘ s tumour characteristics, such as the size of the tumour, the existence of a lymphoma transfer, and the patient ‘ s physical condition, including age, underlying illness, etc. For example, for patients with smaller tumours and HeR2 positives, a combination of breast protection surgery may be considered; breast hysterectomy may be required if the tumour is large or if there is a transfer of lymphoma lymphoma. At the same time, changes in conditions need to be closely monitored during treatment. Regular check-ups, such as video-testing, oncological markers, etc., keep abreast of the development of tumours in order to adjust treatment programmes. If there is a serious adverse reaction in the course of chemotherapy, there may be a need to adjust the doses or to replace the drugs; if there are serious side effects after treatment, there will also be a need for timely treatment and adjustment of treatment plans.
In addition, patients may consider participating in clinical trials. Clinical trials offer patients the opportunity to explore new treatment methods and medicines. There are many ongoing clinical trials for HeR2 positive breast cancer, which may involve new targeting drugs, immunotherapy methods, etc. Participation in clinical trials not only provides patients with up-to-date treatment but also contributes to medical research. Before participating in clinical trials, however, the patient should be fully informed of the purpose, methods, risks and benefits of the trial and take decisions under the guidance of a doctor.
IV. NOTES
Specific treatment programmes require consultation with professional doctors, and the situation varies from patient to patient, so treatment programmes may also differ. Treatment must be conducted under the guidance of a doctor, taking into account the adverse effects of therapeutic drugs, such as bone marrow inhibition, and it is recommended that indicators such as blood protocol, liver function, kidney function, electrolyte, etc. be periodically reviewed during use. For example, different adverse effects may occur when targeting drugs to treat her positive breast cancer. The anti-corrosion can cause adverse effects such as anaemia, insomnia, headaches, haemorrhage, and, in serious cases, ambulatory pulmonary disease, ulterior heart failure, severe liver function impairment, etc., requiring the permanent discontinuation of the drug; the side effects of the inhospital resistance include blood cell reduction, nausea, fever, aminocase increase, heart toxicity, fluid response, etc.; the use of the target for the drug also requires attention to adverse reactions, such as heat, cold warfare, nausea, vomiting, etc., with slight and clearly timely treatment of symptoms. At the same time, doctors must always monitor the vital signs of the patient, in case of unusual and timely examinations and treatment. Patients need to be careful about the mix of diets, less or less of spicy irritating foods and seafood, so as to avoid bacterial infections, leading to inhibition of the immune function and impact on the effects of the target. In addition, patients should actively cooperate with doctors in the treatment process, take care to rest, avoid overwork, maintain adequate sleep, promote disease recovery and control. For patients undergoing chemotherapy, the post-chemical review programme consists mainly of haematological examinations (e.g., blood protocol, liver function, kidney function, tumor markers, etc.), visual examinations (e.g., breast ultrasound, mammogram, chest CT, etc.) and genetic tests, which help doctors to understand the patient ‘ s recovery and assess the effectiveness of the treatment in order to adjust the treatment programme if necessary. Patients who experience abnormal symptoms such as fever, pain, etc. after chemotherapy may be re-emerging or experiencing complications, and should be examined in a timely manner. The specific review project and periodicity shall be arranged on the recommendation of the physician.
